Global Cardiovascular Drugs Market: Overview
Cardiovascular diseases are popularly known as heart diseases. These diseases are associated with circulatory system and heart. To list a few common cardiovascular diseases—rheumatic heart disease, hypertensive heart disease, inflammatory heart disease, ischemic heart disease, and cerebrovascular heart disease. High blood pressure causes hypertensive heart disease. Key concerns related to hypertensive heart disease are hypertrophy, heart failure, angina, and coronary heart disease. Brain blood vessels get affected by the cerebrovascular disease. Cerebrovascular disease common types are a stroke, vascular dementia, transient ischemic attack, and subarachnoid hemorrhage.
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
Global Cardiovascular Drugs Market: Growth Factors
The global cardiovascular disease drug market is anticipated to witness a high growth mainly owing to rising incidences of people suffering from cardiovascular disease. Another major factor positively impacting the growth of the global cardiovascular disease drug market is increasing number of diabetes and obese patients. Increasing geriatric population, unhealthy life style, and the existence of numerous novel drugs in the clinical studies are additional factors boosting the growth of the global cardiovascular disease drug market. Drugs development specifically for numerous applications is, on the other hand, major market restraint faced by key players in the global cardiovascular disease drug market.
Global Cardiovascular Drugs Market: Segmentation
The global cardiovascular disease drug market is segmented on the basis of disease, drug class, and distribution channel. Based on the disease, the global market is classified into cardiac arrhythmias, arteriosclerosis, acute coronary syndrome, myocardial infarction, coronary artery disease, peripheral artery disease, hyperlipidaemia, hypertension, cardiac failure diseases, thrombosis, and others. Based on the drug class, the global cardiovascular disease drug market is diversified as anti-hyperlipidemics, anti-fibrinolytic, anti-hypertensive, anti-arrhythmic, anti-coagulants, and others. The others segment is further sub-segmented as anti-ischemic drugs, anti-anginal drugs, and cardiac glycosides. Based on the distribution channel, the global cardiovascular disease drug market is classified as hospital pharmacies, retail pharmacies, and online pharmacies.
Global Cardiovascular Drugs Market: Regional Analysis
North America is anticipated to dominate the global cardiovascular drugs market in the coming years. The major reason for this growth is rising awareness of numerous heart diseases in this region. Also, the US is expected to witness significant growth in the global cardiovascular drugs market. This trend is flowed by Canada. Moreover, in Europe, the UK, Germany, Italy, France, and Spain grab the major market share. Nevertheless, Asia is anticipated to witness considerable growth in the near future in the global cardiovascular drugs market mainly owing to major players investing R&D facilities in this region.
Global Cardiovascular Drugs Market: Competitive Players
Major players dominating the global cardiovascular disease drug market include Pfizer, Inc., AstraZeneca plc, Merck & Co., Sanofi S.A., Novartis AG, Daiichi Sankyo Company Limited, Takeda Pharmaceutical Company Limited, and Bayer AG. Other key players influencing the global cardiovascular disease drug market are Astellas Pharma Inc., Boehringer Ingelheim GmbH, United Therapeutics Corporation, Johnson & Johnson, Roche Holding AG, and Actelion Pharmaceuticals Ltd.
Global Cardiovascular Drugs Market: Regional Segment Analysis
What Reports Provides
Request the coronavirus impact analysis across industries and markets